CCX168

Phase 2Terminated

0 watching 0 views this week⚡ Active

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

Phase 2

Phase 3

Approved

Indication / Disease

Atypical Hemolytic Uremic Syndrome

Conditions

Atypical Hemolytic Uremic Syndrome

Trial Timeline

Jun 4, 2015 → Jul 13, 2017

NCT ID

NCT02464891

About CCX168

CCX168 is a phase 2 stage product being developed by Amgen for Atypical Hemolytic Uremic Syndrome. The current trial status is terminated. This product is registered under clinical trial identifier NCT02464891. Target conditions include Atypical Hemolytic Uremic Syndrome.

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (3)

NCT ID	Phase	Status	Start	Completion	Indication
NCT05988021	Phase 1	Completed	Dec 3, 2015	May 25, 2016	Anti-neutrophil Cytoplasmic Antibody-associated Vasculitis
NCT02464891	Phase 2	Terminated	Jun 4, 2015	Jul 13, 2017	Atypical Hemolytic Uremic Syndrome
NCT02384317	Phase 2	Completed	Mar 27, 2015	Jun 1, 2018	Immunoglobulin A Nephropathy

Competing Products

18 competing products in Atypical Hemolytic Uremic Syndrome

See all competitors

Product	Company	Stage	Hype Score
Crovalimab	Chugai Pharmaceutical	Phase 3	77
Crovalimab	Chugai Pharmaceutical	Phase 3	77
Duloxetine	Eli Lilly	Approved	85
Teriparatide 20 mcg	Eli Lilly	Phase 3	77
Baricitinib	Eli Lilly	Pre-clinical	23
Ravulizumab	AstraZeneca	Pre-clinical	23
Eculizumab	AstraZeneca	Phase 3	77
Iptacopan	Novartis	Phase 3	77
Iptcaopan 200 mg	Novartis	Phase 3	77
Iptacopan	Novartis	Phase 3	77
Ropeginterferon Alfa-2B	PharmaEssentia	Phase 2	51
Tazemetostat + Nivolumab + Ipilimumab	Bristol Myers Squibb	Phase 1/2	40
Cemdisiran	Alnylam Pharmaceuticals	Phase 2	49
cemdisiran + Placebos	Alnylam Pharmaceuticals	Phase 2	49
Axatilimab + Azacitidine	Incyte	Phase 1/2	38
Gemcitabine + Paxalisib	Pacific Biosciences	Phase 2	44
Apatinib Mesylate	Brain Biotech	Pre-clinical	15
azurin-derived cell-penetrating peptide p28	Brain Biotech	Phase 1	25

Other Products from Amgen